Personalis (NASDAQ:PSNL) Shares Up 6.5% - Time to Buy?

Key Points

• Personalis, Inc. shares surged 6.5% on Thursday, reaching a last traded price of $5.74, despite a significant drop in trading volume compared to the average.
• Analyst ratings reflect a mix of opinions, with five analysts giving a "Buy" rating and a consensus price target of $7.42, while Wall Street Zen downgraded the stock to a "sell" rating.
• The company reported a quarterly loss of ($0.23) EPS, exceeding analysts' expectations, although revenue fell short of forecasts, highlighting ongoing financial challenges.

Personalis, Inc. (NASDAQ:PSNL - Get Free Report) rose 6.5% during mid-day trading on Thursday . The stock traded as high as $5.64 and last traded at $5.74. Approximately 72,238 shares changed hands during trading, a decline of 93% from the average daily volume of 1,042,834 shares. The stock had previously closed at $5.39.

Wall Street Analysts Forecast Growth

PSNL has been the subject of several analyst reports. BTIG Research set a $6.00 price objective on Personalis in a research report on Wednesday, August 6th. Wall Street Zen downgraded Personalis from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th. Finally, HC Wainwright restated a "buy" rating and issued a $8.50 target price on shares of Personalis in a research report on Monday, September 8th. Five equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $7.42.

Personalis Stock Performance

The firm's 50 day simple moving average is $5.48 and its 200-day simple moving average is $4.88. The company has a market capitalization of $520.53 million, a price-to-earnings ratio of -4.59 and a beta of 1.76.

Personalis (NASDAQ:PSNL - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.02. Personalis had a negative net margin of 113.70% and a negative return on equity of 47.57%. The company had revenue of $17.20 million for the quarter, compared to the consensus estimate of $20.12 million. Personalis has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, equities analysts anticipate that Personalis, Inc. will post -1.4 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Personalis

A number of hedge funds have recently modified their holdings of PSNL. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Personalis in the fourth quarter worth $28,000. Legal & General Group Plc bought a new stake in Personalis in the second quarter worth $30,000. Ameritas Investment Partners Inc. bought a new stake in Personalis in the second quarter worth $34,000. BNP Paribas Financial Markets boosted its holdings in Personalis by 406.4% in the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company's stock worth $42,000 after purchasing an additional 5,177 shares in the last quarter. Finally, Focus Partners Wealth bought a new stake in Personalis in the first quarter worth $47,000. 61.91% of the stock is owned by institutional investors and hedge funds.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.